Initial study results show benefits of Alpharadin

06/30/2009 | Daily Express (London)

Alpharadin, an injectable drug containing a radioactive isotope, is becoming a viable option for prostate cancer patients whose cancer has metastasized to the bone or those who no longer respond to other treatments. The drug, which is in final Phase III trials, can precisely target and treat metastatic cancer in bones to spare healthy cells. "Results have been very positive and have suggested it is increasing survival rates," said a doctor who is part of the study.

View Full Article in:

Daily Express (London)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations